Citations to this article


Persistently activated or tyrosine-phosphorylated STAT3 (pSTAT3) is found in 50% of lung adenocarcinomas. pSTAT3 is found in primary adenocarcinomas and cell lines harboring somatic-activating mutations in the tyrosine kinase domain of EGFR. Treatment of cell lines with either an EGFR inhibitor or an src kinase inhibitor had no effect on pSTAT3 levels, whereas a pan-JAK inhibitor (P6) blocked activation of STAT3 and inhibited tumorigenesis. Cell lines expressing these persistently activated mutant EGFRs also produced high IL-6 levels, and blockade of the IL-6/gp130/JAK pathway led to a decrease in pSTAT3 levels. In addition, reduction of IL-6 levels by RNA interference led to a decrease in tumorigenesis. Introduction of persistently activated EGFR into immortalized breast epithelial cells led to tumorigenesis, IL-6 expression, and STAT3 activation, all of which could be inhibited with P6 or gp130 blockade. Furthermore, inhibition of EGFR activity in multiple cell lines partially blocked transcription of IL-6 and concurrently decreased production and release of IL-6. Finally, immunohistochemical analysis revealed a positive correlation between pSTAT3 and IL-6 positivity in primary lung adenocarcinomas. Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment.


Sizhi Paul Gao ... Bayard Clarkson, Jacqueline F. Bromberg


Total citations by year

Year: 2015 2014 2013 2012 2011 2010 2009 2008 2007 Total
Citations: 19 55 32 33 29 26 31 16 1 242
Citation information

Citations to this article in year 2010 (26)

Title and authors Publication Year
SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo
WR Chao, K Amin, Y Shi, P Hobbs, M Tanabe, M Tanga, L Jong, N Collins, R Peters, K Laderoute, D Dinh, D Yean, C Hou, B Sato, C Alt, L Sambucetti
Angiogenesis 2010
A systems view of epithelial–mesenchymal transition signaling states
S Thomson, F Petti, I Sujka-Kwok, P Mercado, J Bean, M Monaghan, SL Seymour, GM Argast, DM Epstein, JD Haley
Clinical & Experimental Metastasis 2010
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer
R Rosell, S Viteri, MA Molina, S Benlloch, M Taron
Current Opinion in Oncology 2010
Immunity, Inflammation, and Cancer
SI Grivennikov, FR Greten, M Karin
Cell 2010
Ultraviolet light induces Stat3 activation in human keratinocytes and fibroblasts through reactive oxygen species and DNA damage
T Bito, N Sumita, T Masaki, T Shirakawa, M Ueda, R Yoshiki, Y Tokura, C Nishigori
Experimental Dermatology 2010
Molecular pathways and targets in cancer-related inflammation
A Mantovani, C Garlanda, P Allavena
Annals of Medicine 2010
Salivary IL-6 levels in oral leukoplakia with dysplasia and its clinical relevance to tobacco habits and periodontitis
M Sharma, I Bairy, K Pai, K Satyamoorthy, S Prasad, B Berkovitz, R Radhakrishnan
Clinical Oral Investigations 2010
Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance
J Cherfils-Vicini, S Platonova, M Gillard, L Laurans, P Validire, R Caliandro, P Magdeleinat, F Mami-Chouaib, MC Dieu-Nosjean, WH Fridman, D Damotte, C Sautès-Fridman, I Cremer
Journal of Clinical Investigation 2010
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches
SY Lai, FM Johnson
Drug Resistance Updates 2010
Inflaming resistance to Tarceva
C Cain
Science-Business eXchange 2010
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
S Marubayashi, P Koppikar, T Taldone, O Abdel-Wahab, N West, N Bhagwat, E Caldas-Lopes, KN Ross, M Gönen, A Gozman, JH Ahn, A Rodina, O Ouerfelli, G Yang, C Hedvat, JE Bradner, G Chiosis, RL Levine
Journal of Clinical Investigation 2010
A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance
EB Haura, E Sommers, L Song, A Chiappori, A Becker
Journal of Thoracic Oncology 2010
Reactive oxygen species involved in sulforaphane-induced STAT3 inactivation and apoptosis in DU145 prostate cancer cells
W Koh, KS Ahn, SJ Jeong, HJ Lee, M Kim, HJ Lee, EO Lee, SH Kim
Chinese Science Bulletin 2010
Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib
K Masago, S Fujita, Y Togashi, YH Kim, Y Hatachi, A Fukuhara, H Nagai, K Irisa, Y Sakamori, C Okuda, T Mio, M Mishima
Oncology 2010
Aberrant DNA methylation profile in cholangiocarcinoma
L Huang, G Frampton, LJ Liang, S Demorrow
World journal of gastrointestinal pathophysiology 2010
Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells
WL Huang, HH Yeh, CC Lin, WW Lai, JY Chang, WT Chang, WC Su
Molecular Cancer 2010
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
H Lee, J Deng, M Kujawski, C Yang, Y Liu, A Herrmann, M Kortylewski, D Horne, G Somlo, S Forman, R Jove, H Yu
Nature Medicine 2010
Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation
K Leslie, SP Gao, M Berishaj, K Podsypanina, H Ho, L Ivashkiv, J Bromberg
Breast Cancer Research 2010
Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?
A Jarnicki, T Putoczki, M Ernst
Cell division 2010
Early administration of IL-6RA does not prevent radiation-induced lung injury in mice
T Ogata, H Yamazaki, T Teshima, A Kihara, Y Suzumoto, T Inoue, N Nishimoto, N Matsuura
Radiation oncology (London, England) 2010
Significance of Interleukin-6 Signaling in the Resistance of Pharyngeal Cancer to Irradiation and the Epidermal Growth Factor Receptor Inhibitor
CC Chen, WC Chen, CH Lu, WH Wang, PY Lin, KD Lee, MF Chen
International journal of radiation oncology, biology, physics 2010
Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine Lif
Y Chen, J Deng, J Fujimoto, H Kadara, T Men, D Lotan, R Lotan
Cancer research 2010
Inhibition of STAT3 Signaling Blocks the Anti-apoptotic Activity of IL-6 in Human Liver Cancer Cells*
Y Liu, PK Li, C Li, J Lin
The Journal of biological chemistry 2010
Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin
J Zhou, CN Ong, GM Hur, HM Shen
Biochemical Pharmacology 2010
Regenerating gene I regulates interleukin-6 production in squamous esophageal cancer cells
S Usami, S Motoyama, S Koyota, J Wang, K Hayashi-Shibuya, K Maruyama, N Takahashi, H Saito, Y Minamiya, S Takasawa, J Ogawa, T Sugiyama
Biochemical and Biophysical Research Communications 2010